gentamicin has been researched along with Adverse Drug Event in 34 studies
Gentamicins: A complex of closely related aminoglycosides obtained from MICROMONOSPORA purpurea and related species. They are broad-spectrum antibiotics, but may cause ear and kidney damage. They act to inhibit PROTEIN BIOSYNTHESIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Patients aged 15-60 years diagnosed with uncomplicated urogenital gonorrhea were randomly assigned to either gentamicin 240 mg intramuscularly plus azithromycin 2 g orally, or gemifloxacin 320 mg orally plus azithromycin 2 g orally." | 9.19 | The efficacy and safety of gentamicin plus azithromycin and gemifloxacin plus azithromycin as treatment of uncomplicated gonorrhea. ( Ghanem, KG; Hook, EW; Johnson, S; Kerndt, PR; Kirkcaldy, RD; Moore, PC; Papp, JR; Philip, SS; Weinstock, HS; Wiesenfeld, HC, 2014) |
| " Patients aged 15-60 years diagnosed with uncomplicated urogenital gonorrhea were randomly assigned to either gentamicin 240 mg intramuscularly plus azithromycin 2 g orally, or gemifloxacin 320 mg orally plus azithromycin 2 g orally." | 5.19 | The efficacy and safety of gentamicin plus azithromycin and gemifloxacin plus azithromycin as treatment of uncomplicated gonorrhea. ( Ghanem, KG; Hook, EW; Johnson, S; Kerndt, PR; Kirkcaldy, RD; Moore, PC; Papp, JR; Philip, SS; Weinstock, HS; Wiesenfeld, HC, 2014) |
| "The current experiment aimed to identify the possible protective role of rivastigmine (RIVA) in gentamicin (GNT)-induced acute kidney injury (AKI) in rats." | 4.31 | Rivastigmine ameliorates gentamicin experimentally induced acute renal toxicity. ( Abdelzaher, WY; AboBakr Ali, AHS; Aly Labib, DA; El-Tahawy, NFG; Mohamed, HA; Welson, NN, 2023) |
| "Gentamicin nephrotoxicity was characterized by a significant rise in serum urea and creatinine levels and a significant reduction in body weight and an increase in kidney weight/body weight." | 4.12 | Protective Effect of Curcumin Against Gentamicin-induced Nephrotoxicity Mediated by p38 MAPK, Nuclear Factor- Kappa B, Nuclear Factor Erythroid 2-Related Factor 2. ( Uz, YH; Uzun-Goren, D, 2022) |
| "Gentamicin induced a consistent reduction in VOR responses and a progressive high-frequency hearing loss of 50-60 dB sound pressure level." | 3.72 | Protective effects of alpha-tocopherol against gentamicin-induced Oto-vestibulo toxicity: an experimental study. ( Ferraresi, A; Fetoni, AR; Paludetti, G; Scarano, E; Sergi, B; Troiani, D, 2003) |
| "To systematically review the frequency and type of adverse events associated with a single dose of intravenous or intramuscular gentamicin in adults, for any indication, in studies where a comparator was available." | 2.58 | Adverse effects of a single dose of gentamicin in adults: a systematic review. ( Harding, J; Hayward, RS; Land, L; Longcroft-Neal, K; Molloy, R; Moore, D; Ross, JDC, 2018) |
| " Conversely paediatric studies have shown lower rates and extended interval dosing may have reduced toxicity further." | 2.50 | Aminoglycoside toxicity in neonates: something to worry about? ( Heath, PT; Kent, A; Sharland, M; Turner, MA, 2014) |
| " Thus, the model is generalizable, and can be used to deconvolute the underlying degree and time course of drug-induced PT injury and renal dysfunction from a small number of urinary biomarkers, and may provide a tool to determine optimal dosing regimens that minimize renal injury." | 1.48 | Multiscale Mathematical Model of Drug-Induced Proximal Tubule Injury: Linking Urinary Biomarkers to Epithelial Cell Injury and Renal Dysfunction. ( Gebremichael, Y; Hallow, KM; Helmlinger, G; Lu, J; Mettetal, J; Shankaran, H, 2018) |
| "Treatment of infections in neonates with gentamicin is a balance between optimising bactericidal effect and minimising adverse effects." | 1.46 | A simple high-dose gentamicin regimen showed no side effects among neonates. ( Blaabjerg, AS; Dalegaard, MC; Fenger-Gron, J; Kofoed, PE, 2017) |
| "Gentamicin was given at 2." | 1.42 | Pharmacokinetics of gentamicin in newborns with moderate-to-severe hypoxic-ischemic encephalopathy undergoing therapeutic hypothermia. ( Kwan, E; McDougal, A; Osiovich, H; Ting, JY, 2015) |
| "The adverse effect to the inner ear of aminoglycosides, drugs widely administered for the treatment of serious infections, appears to result from the interaction of these drugs with Cu(II) or Fe(II)/Fe(III) ions." | 1.32 | Solution chemistry of copper(II)-gentamicin complexes: relevance to metal-related aminoglycoside toxicity. ( Harris, WR; Kravitz, JY; Lesniak, W; Pecoraro, VL; Schacht, J, 2003) |
| "Determination of potential drug toxicity and side effect in early stages of drug development is important in reducing the cost and time of drug discovery." | 1.31 | Prediction of potential toxicity and side effect protein targets of a small molecule by a ligand-protein inverse docking approach. ( Chen, YZ; Ung, CY, 2001) |
| "In chloroquine-treated cells, the EC50 values were 110." | 1.31 | Evaluation of the cytotoxicity of selected systemic and intravitreally dosed drugs in the cultures of human retinal pigment epithelial cell line and of pig primary retinal pigment epithelial cells. ( Diehl, H; Engelke, M; Huhtala, A; Mäenpää, H; Mannerström, M; Mäntylä, E; Mäntylä, M; Marselos, M; Pappas, P; Salminen, L; Tähti, H; Toimela, T; Uusitalo, H; Zorn-Kruppa, M, 2002) |
| "However, alcohol addiction was not considered in these studies." | 1.29 | Adverse drug reactions (ADRs) in patients with previous history of chronic alcohol consumption without signs of chronic hepatic damage. A prospective study. ( Díaz, M; Dominichinni, H; Gonzáles-Martín, G; Guevara, A, 1995) |
| "Once an adverse drug reaction has been identified, the patient should be informed and appropriate documentation made in the patient's medical record." | 1.28 | Recognizing and reporting adverse drug reactions. ( Colley, CA; Lucas, LM, 1992) |
| "gentamicin therapy were randomly selected and monitored for possible ADRs." | 1.27 | Sensitivity and specificity of three methods of detecting adverse drug reactions. ( Berry, LL; Fudge, KA; Segal, R; Sherrin, TP, 1988) |
| "It is common practice in the clinical setting to adjust the dosage of a drug administered to a patient with altered pharmacokinetic characteristics, e." | 1.27 | Exponential intravenous infusions in toxicological studies: achieving identical serum drug concentration profiles in individuals with altered pharmacokinetic states. ( Cooperstein, M; Dix, LP; Frazier, DL; Riviere, JE, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (23.53) | 18.7374 |
| 1990's | 3 (8.82) | 18.2507 |
| 2000's | 7 (20.59) | 29.6817 |
| 2010's | 13 (38.24) | 24.3611 |
| 2020's | 3 (8.82) | 2.80 |
| Authors | Studies |
|---|---|
| Uzun-Goren, D | 1 |
| Uz, YH | 1 |
| Abdelzaher, WY | 3 |
| El-Tahawy, NFG | 3 |
| AboBakr Ali, AHS | 3 |
| Mohamed, HA | 3 |
| Welson, NN | 3 |
| Aly Labib, DA | 3 |
| Ashrafi, MR | 1 |
| Khalili, A | 1 |
| Hashemi, SA | 1 |
| Mazloom, R | 1 |
| Changizi-Ashtiyani, S | 1 |
| Bayat, G | 1 |
| Blaabjerg, AS | 1 |
| Kofoed, PE | 1 |
| Dalegaard, MC | 1 |
| Fenger-Gron, J | 1 |
| Hayward, RS | 2 |
| Harding, J | 1 |
| Molloy, R | 1 |
| Land, L | 1 |
| Longcroft-Neal, K | 1 |
| Moore, D | 1 |
| Ross, JDC | 1 |
| Gebremichael, Y | 1 |
| Lu, J | 1 |
| Shankaran, H | 1 |
| Helmlinger, G | 1 |
| Mettetal, J | 1 |
| Hallow, KM | 1 |
| Halmagyi, GM | 1 |
| Curthoys, IS | 1 |
| Kent, A | 1 |
| Turner, MA | 1 |
| Sharland, M | 1 |
| Heath, PT | 1 |
| Kirkcaldy, RD | 1 |
| Weinstock, HS | 1 |
| Moore, PC | 1 |
| Philip, SS | 1 |
| Wiesenfeld, HC | 1 |
| Papp, JR | 1 |
| Kerndt, PR | 1 |
| Johnson, S | 1 |
| Ghanem, KG | 1 |
| Hook, EW | 1 |
| Ting, JY | 1 |
| Kwan, E | 1 |
| McDougal, A | 1 |
| Osiovich, H | 1 |
| Adil, M | 1 |
| Kandhare, AD | 1 |
| Dalvi, G | 1 |
| Ghosh, P | 1 |
| Venkata, S | 1 |
| Raygude, KS | 1 |
| Bodhankar, SL | 1 |
| Ahmed, I | 1 |
| Khan, MA | 1 |
| Allgar, V | 1 |
| Mohsen, A | 1 |
| Slater, MB | 1 |
| Gruneir, A | 1 |
| Rochon, PA | 1 |
| Howard, AW | 1 |
| Koren, G | 1 |
| Parshuram, CS | 1 |
| Vaidya, VS | 1 |
| Ozer, JS | 2 |
| Dieterle, F | 2 |
| Collings, FB | 1 |
| Ramirez, V | 1 |
| Troth, S | 2 |
| Muniappa, N | 2 |
| Thudium, D | 1 |
| Gerhold, D | 1 |
| Holder, DJ | 1 |
| Bobadilla, NA | 1 |
| Marrer, E | 1 |
| Perentes, E | 2 |
| Cordier, A | 2 |
| Vonderscher, J | 2 |
| Maurer, G | 2 |
| Goering, PL | 1 |
| Sistare, FD | 2 |
| Bonventre, JV | 1 |
| Verdes, P | 1 |
| Staedtler, F | 1 |
| Mahl, A | 1 |
| Grenet, O | 1 |
| Roth, DR | 1 |
| Wahl, D | 1 |
| Legay, F | 1 |
| Holder, D | 1 |
| Erdos, Z | 1 |
| Vlasakova, K | 1 |
| Jin, H | 1 |
| Yu, Y | 1 |
| Forest, T | 1 |
| Clouse, HK | 1 |
| Reynolds, S | 1 |
| Bailey, WJ | 1 |
| Thudium, DT | 1 |
| Topper, MJ | 1 |
| Skopek, TR | 1 |
| Sina, JF | 1 |
| Glaab, WE | 1 |
| Chibout, SD | 1 |
| Gerhold, DL | 1 |
| Lesniak, W | 1 |
| Harris, WR | 1 |
| Kravitz, JY | 1 |
| Schacht, J | 1 |
| Pecoraro, VL | 1 |
| Fetoni, AR | 1 |
| Sergi, B | 1 |
| Scarano, E | 1 |
| Paludetti, G | 1 |
| Ferraresi, A | 1 |
| Troiani, D | 1 |
| Witzmann, FA | 1 |
| Li, J | 1 |
| Erickson, SB | 1 |
| Gonzáles-Martín, G | 1 |
| Dominichinni, H | 1 |
| Díaz, M | 1 |
| Guevara, A | 1 |
| Reiss, M | 1 |
| Maltezou, HC | 1 |
| Baka, M | 1 |
| Gombakis, N | 1 |
| Koliouskas, DE | 1 |
| Kosmidou, H | 1 |
| Malaka-Zafiriou, E | 1 |
| Kafetzis, DA | 1 |
| Pedersen, CA | 1 |
| Schneider, PJ | 1 |
| Chen, YZ | 1 |
| Ung, CY | 1 |
| Mannerström, M | 1 |
| Zorn-Kruppa, M | 1 |
| Diehl, H | 1 |
| Engelke, M | 1 |
| Toimela, T | 1 |
| Mäenpää, H | 1 |
| Huhtala, A | 1 |
| Uusitalo, H | 1 |
| Salminen, L | 1 |
| Pappas, P | 1 |
| Marselos, M | 1 |
| Mäntylä, M | 1 |
| Mäntylä, E | 1 |
| Tähti, H | 1 |
| Hammond, KB | 1 |
| Abt, C | 1 |
| Dietrich, M | 1 |
| Niethammer, D | 1 |
| Arnold, R | 1 |
| Pflieger, H | 1 |
| Töllner, U | 1 |
| Vanek, E | 1 |
| Kubanek, B | 1 |
| Kleihauer, E | 1 |
| Heimpel, H | 1 |
| Despaux, N | 1 |
| Duprey, F | 1 |
| Bohuon, C | 1 |
| Boudène, C | 1 |
| Lucas, LM | 1 |
| Colley, CA | 1 |
| Berry, LL | 1 |
| Segal, R | 1 |
| Sherrin, TP | 1 |
| Fudge, KA | 1 |
| Dix, LP | 1 |
| Frazier, DL | 1 |
| Cooperstein, M | 1 |
| Riviere, JE | 1 |
| Goicoechea, FJ | 1 |
| Jelliffe, RW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized Clinical Trial Evaluating the Efficacy of Gentamicin/Azithromycin and Gemifloxacin/Azithromycin Combination Therapies as an Alternative Regimen for Uncomplicated Urogenital Gonorrhea[NCT00926796] | Phase 4 | 614 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| Predicting Acute Kidney Injury in Infants Exposed to Nephrotoxic Drugs: A Big Data Approach to Predict NEOnatal Acute Kidney Injury in Newborns expoSed to nephroTOxic Drugs. (NeoAKI STOP)[NCT05851222] | 4,200 participants (Anticipated) | Observational | 2023-08-01 | Not yet recruiting | |||
| Comparison Effect Between Lower Pressure and Standard Pressure Pneumoperitoneum on Sign of Acute Systemic Inflammation, Endothelial Injury, and Acute Kidney Injury: A Randomized Clinical Trial in Living Donor Laparoscopic Nephrectomy[NCT03219398] | 44 participants (Actual) | Interventional | 2017-08-01 | Completed | |||
| Assessment of Renal Tubular Injury and Transplant Outcomes in Cardiac Recipients Converting From Immediate Release Tacrolimus to Extended Release Tacrolimus.[NCT04917718] | Phase 4 | 42 participants (Anticipated) | Interventional | 2021-08-16 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Number of enrollees with positive pharyngeal culture at enrollment who have negative culture 10-17 days after treatment (NCT00926796)
Timeframe: 10-17 days after treatment.
| Intervention | participants (Number) |
|---|---|
| Regimen A: Gentamicin Plus Azithromycin | 10 |
| Regimen B: Gemifloxacin Plus Azithromycin | 15 |
Number of enrollees with positive rectal culture at enrollment who have negative culture 10-17 days after treatment (NCT00926796)
Timeframe: 10-17 days after treatment.
| Intervention | participants (Number) |
|---|---|
| Regimen A: Gentamicin Plus Azithromycin | 1 |
| Regimen B: Gemifloxacin Plus Azithromycin | 5 |
Percentage of enrollees negative by culture at cervix/urethra 10-17 days after treatment, regardless of history of re-exposure, among those with positive gonococcal cultures at enrollment (microbiological cure) (NCT00926796)
Timeframe: 10-17 days after treatment.
| Intervention | percentage of participants (Number) |
|---|---|
| Regimen B: Gemifloxacin Plus Azithromycin | 99.50 |
Percentage of enrollees negative by culture at cervix/urethra 10-17 days after treatment, regardless of history of re-exposure, among those with positive gonococcal cultures at enrollment (microbiological cure) (NCT00926796)
Timeframe: 10-17 days after treatment.
| Intervention | percentage of participants (Number) |
|---|---|
| Regimen A: Gentamicin Plus Azithromycin | 100 |
Number of treated participants experiencing mild, moderate, severe, or life-threatening adverse events (AEs) either temporarily associated or not associated with study product. (NCT00926796)
Timeframe: Day 0 through Day 30
| Intervention | participants (Number) |
|---|---|
| Regimen A: Gentamicin Plus Azithromycin | 157 |
| Regimen B: Gemifloxacin Plus Azithromycin | 185 |
Number of participants whose gonorrhea-related symptoms (e.g. vaginal/urethral discharge, dysuria, dyspareunia) present at enrollment has resolved by visit 2. (NCT00926796)
Timeframe: 10-17 days after treatment.
| Intervention | participants (Number) |
|---|---|
| Regimen A: Gentamicin Plus Azithromycin | 179 |
| Regimen B: Gemifloxacin Plus Azithromycin | 177 |
Minimum inhibitory concentration (micrograms/milliliter) of pretreatment gonorrhea isolates collected from participants (NCT00926796)
Timeframe: Isolates obtained at enrollment (Day 0).
| Intervention | micrograms/milliliter (Median) | |||||||
|---|---|---|---|---|---|---|---|---|
| Azithromycin | Cefixime | Ceftriaxone | Ciprofloxacin | Gemifloxacin | Gentamicin | Penicillin | Tetracycline | |
| Baseline | 0.25 | 0.015 | 0.008 | 0.004 | 0.004 | 4 | 0.5 | 0.5 |
For treatment failures (i.e., participants with positive culture at cervix/urethra 10-17 days after treatment), the minimum inhibitory concentrations for various antimicrobial agents (Azithromycin, Cefixime, Ceftriaxone, Ciprofloxacin, Gemifloxacin, Gentamicin, Penicillin, Tetracycline). (NCT00926796)
Timeframe: Isolates obtained at enrollment (Day 0).
| Intervention | micrograms/milliliter (Median) | |||||||
|---|---|---|---|---|---|---|---|---|
| Azithromycin | Cefixime | Ceftriaxone | Ciprofloxacin | Gemifloxacin | Gentamicin | Penicillin | Tetracycline | |
| Regimen B: Gemifloxacin Plus Azithromycin | 0.25 | 0.015 | 0.004 | 0.002 | 0.004 | 4 | 0.5 | 0.25 |
For treatment failures (i.e., participants with positive culture at cervix/urethra 10-17 days after treatment), number participants with clinical symptoms (vaginal/urethral discharge, dysuria, dyspareunia) at 10-17 days. (NCT00926796)
Timeframe: 10-17 days
| Intervention | participants (Number) | ||
|---|---|---|---|
| Vaginal/urethral discharge | Dysuria | Dyspareunia | |
| Regimen B: Gemifloxacin Plus Azithromycin | 0 | 0 | 0 |
4 reviews available for gentamicin and Adverse Drug Event
| Article | Year |
|---|---|
Adverse effects of a single dose of gentamicin in adults: a systematic review.
Topics: Acute Kidney Injury; Adult; Anti-Bacterial Agents; Bias; Dose-Response Relationship, Drug; Drug-Rela | 2018 |
Aminoglycoside toxicity in neonates: something to worry about?
Topics: Amikacin; Aminoglycosides; Animals; Anti-Infective Agents; Drug-Related Side Effects and Adverse Rea | 2014 |
Proteomics and nephrotoxicity.
Topics: Drug-Related Side Effects and Adverse Reactions; Electrophoresis, Gel, Two-Dimensional; Gentamicins; | 2004 |
Drugs and children: methods for therapeutic monitoring.
Topics: Carbamazepine; Child; Child, Preschool; Chloramphenicol; Chromatography, Gas; Colorimetry; Drug Ther | 1977 |
2 trials available for gentamicin and Adverse Drug Event
| Article | Year |
|---|---|
The efficacy and safety of gentamicin plus azithromycin and gemifloxacin plus azithromycin as treatment of uncomplicated gonorrhea.
Topics: Administration, Oral; Adolescent; Adult; Anti-Bacterial Agents; Azithromycin; Drug Therapy, Combinat | 2014 |
Comparison of isepamicin with amikacin for the empirical treatment of febrile neutropenic children with malignancies.
Topics: Amikacin; Anti-Bacterial Agents; Bacterial Infections; Child; Child, Preschool; Drug-Related Side Ef | 2001 |
28 other studies available for gentamicin and Adverse Drug Event
| Article | Year |
|---|---|
Protective Effect of Curcumin Against Gentamicin-induced Nephrotoxicity Mediated by p38 MAPK, Nuclear Factor- Kappa B, Nuclear Factor Erythroid 2-Related Factor 2.
Topics: Animals; Body Weight; Curcumin; Drug-Related Side Effects and Adverse Reactions; Gentamicins; Kidney | 2022 |
Rivastigmine ameliorates gentamicin experimentally induced acute renal toxicity.
Topics: Acute Kidney Injury; Animals; Drug-Related Side Effects and Adverse Reactions; Gentamicins; Kidney; | 2023 |
Rivastigmine ameliorates gentamicin experimentally induced acute renal toxicity.
Topics: Acute Kidney Injury; Animals; Drug-Related Side Effects and Adverse Reactions; Gentamicins; Kidney; | 2023 |
Rivastigmine ameliorates gentamicin experimentally induced acute renal toxicity.
Topics: Acute Kidney Injury; Animals; Drug-Related Side Effects and Adverse Reactions; Gentamicins; Kidney; | 2023 |
Rivastigmine ameliorates gentamicin experimentally induced acute renal toxicity.
Topics: Acute Kidney Injury; Animals; Drug-Related Side Effects and Adverse Reactions; Gentamicins; Kidney; | 2023 |
Role of Farnesoid Receptors and Nrf2-mediated Genes in Gentamicin-induced Nephrotoxicity in Rat: A Time-course Study.
Topics: Animals; Drug-Related Side Effects and Adverse Reactions; Gentamicins; Kidney; Male; NF-E2-Related F | 2023 |
A simple high-dose gentamicin regimen showed no side effects among neonates.
Topics: Anti-Bacterial Agents; Bacterial Infections; Clinical Protocols; Denmark; Drug-Related Side Effects | 2017 |
Multiscale Mathematical Model of Drug-Induced Proximal Tubule Injury: Linking Urinary Biomarkers to Epithelial Cell Injury and Renal Dysfunction.
Topics: Acute Kidney Injury; Animals; Biomarkers; Cisplatin; Drug Development; Drug-Related Side Effects and | 2018 |
Adverse effects of a single dose of gentamicin.
Topics: Adult; Anti-Bacterial Agents; Drug Administration Schedule; Drug-Related Side Effects and Adverse Re | 2018 |
Response to 'Adverse effects of a single dose of gentamicin' by Halmagyi and Curthoys.
Topics: Adult; Drug-Related Side Effects and Adverse Reactions; Gentamicins; Humans | 2018 |
Pharmacokinetics of gentamicin in newborns with moderate-to-severe hypoxic-ischemic encephalopathy undergoing therapeutic hypothermia.
Topics: Anti-Bacterial Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Dosage C | 2015 |
Ameliorative effect of berberine against gentamicin-induced nephrotoxicity in rats via attenuation of oxidative stress, inflammation, apoptosis and mitochondrial dysfunction.
Topics: Acute-Phase Proteins; Animals; Anti-Bacterial Agents; Apoptosis; Berberine; Blood Urea Nitrogen; Cel | 2016 |
The effectiveness and safety of two prophylactic antibiotic regimes in hip-fracture surgery.
Topics: Aged, 80 and over; Anti-Bacterial Agents; Antibiotic Prophylaxis; Cefuroxime; Drug Therapy, Combinat | 2016 |
Identifying High-Risk Medications Associated with Acute Kidney Injury in Critically Ill Patients: A Pharmacoepidemiologic Evaluation.
Topics: Acute Kidney Injury; Adolescent; Case-Control Studies; Child; Child, Preschool; Critical Illness; Dr | 2017 |
Kidney injury molecule-1 outperforms traditional biomarkers of kidney injury in preclinical biomarker qualification studies.
Topics: Acetylglucosaminidase; Animals; Biomarkers, Pharmacological; Blood Urea Nitrogen; Cell Adhesion Mole | 2010 |
Kidney injury molecule-1 outperforms traditional biomarkers of kidney injury in preclinical biomarker qualification studies.
Topics: Acetylglucosaminidase; Animals; Biomarkers, Pharmacological; Blood Urea Nitrogen; Cell Adhesion Mole | 2010 |
Kidney injury molecule-1 outperforms traditional biomarkers of kidney injury in preclinical biomarker qualification studies.
Topics: Acetylglucosaminidase; Animals; Biomarkers, Pharmacological; Blood Urea Nitrogen; Cell Adhesion Mole | 2010 |
Kidney injury molecule-1 outperforms traditional biomarkers of kidney injury in preclinical biomarker qualification studies.
Topics: Acetylglucosaminidase; Animals; Biomarkers, Pharmacological; Blood Urea Nitrogen; Cell Adhesion Mole | 2010 |
A panel of urinary biomarkers to monitor reversibility of renal injury and a serum marker with improved potential to assess renal function.
Topics: Animals; Biomarkers, Pharmacological; Blood Urea Nitrogen; Carbapenems; Creatinine; Cystatin C; Drug | 2010 |
Solution chemistry of copper(II)-gentamicin complexes: relevance to metal-related aminoglycoside toxicity.
Topics: Anti-Bacterial Agents; Blood Chemical Analysis; Chromatography, High Pressure Liquid; Circular Dichr | 2003 |
Protective effects of alpha-tocopherol against gentamicin-induced Oto-vestibulo toxicity: an experimental study.
Topics: alpha-Tocopherol; Animals; Auditory Threshold; Disease Models, Animal; Drug Interactions; Drug-Relat | 2003 |
A rational approach to nephrotoxic drugs in the elderly.
Topics: Aged; Analgesics; Contrast Media; Drug-Related Side Effects and Adverse Reactions; Gentamicins; Gold | 1980 |
Adverse drug reactions (ADRs) in patients with previous history of chronic alcohol consumption without signs of chronic hepatic damage. A prospective study.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Alcohol Drinking; Alcoholis | 1995 |
[When do ear drops help, when are they harmful?].
Topics: Administration, Topical; Chloramphenicol; Contraindications; Drug-Related Side Effects and Adverse R | 1999 |
Vital signs of quality: medication-use safety.
Topics: Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Gentamicins; Humans; Monitoring, Phys | 2001 |
Prediction of potential toxicity and side effect protein targets of a small molecule by a ligand-protein inverse docking approach.
Topics: Ascorbic Acid; Aspirin; Computer Simulation; Drug-Related Side Effects and Adverse Reactions; Gentam | 2001 |
Evaluation of the cytotoxicity of selected systemic and intravitreally dosed drugs in the cultures of human retinal pigment epithelial cell line and of pig primary retinal pigment epithelial cells.
Topics: Animals; Cell Division; Cell Survival; Cells, Cultured; Chloroquine; Dose-Response Relationship, Dru | 2002 |
[Acute drug-induced agranulocytosis: comparison between openward treatment and antimicrobial decontamination in a plastic isolation bed system (retrospective study of 30 cases) (author's transl)].
Topics: Adolescent; Adult; Aged; Agranulocytosis; Bacterial Infections; Blood Transfusion; Carbenicillin; Ch | 1978 |
[Radioimmunoassays. Their application in toxicology (author's transl)].
Topics: Antigens; Cardiac Glycosides; Digitalis Glycosides; Drug-Related Side Effects and Adverse Reactions; | 1976 |
Recognizing and reporting adverse drug reactions.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Decision Making; Drug-Related Side Effects and Adver | 1992 |
Sensitivity and specificity of three methods of detecting adverse drug reactions.
Topics: Algorithms; Computers; Data Collection; Digoxin; Drug-Related Side Effects and Adverse Reactions; Ge | 1988 |
Exponential intravenous infusions in toxicological studies: achieving identical serum drug concentration profiles in individuals with altered pharmacokinetic states.
Topics: Animals; Dogs; Drug-Related Side Effects and Adverse Reactions; Female; Gentamicins; Infusions, Pare | 1986 |
Drug-induced deafness.
Topics: Adult; Anti-Bacterial Agents; Aspirin; Deafness; Drug-Related Side Effects and Adverse Reactions; Et | 1973 |
Computerized dosage regimens for highly toxic drugs.
Topics: Blood Urea Nitrogen; Cardiac Glycosides; Computers; Creatinine; Drug Evaluation; Drug-Related Side E | 1974 |